LEO Pharma
UnverifiedManufacturerMadison, New Jersey (US affiliate); parent LEO Pharma A/S headquartered in DenmarkFounded 1908
Overview
LEO Pharma Inc., based in Madison, New Jersey, is the U.S. affiliate of Denmark-based LEO Pharma A/S, a medical dermatology company founded in 1908 and majority owned by the LEO Foundation. Its U.S. products include Adbry (tralokinumab), Anzupgo (delgocitinib) cream and Spevigo (spesolimab-szbo), alongside topical brands such as Enstilar, Finacea and Taclonex. U.S. field teams cover general medical dermatology and rare dermatology separately.
Hiring snapshot
Hiring by specialty
Open roles
Newest first, from LEO Pharma’s careers page.
- Rare Disease Sales ConsultantPhoenix, Arizona4d ago$150k–$215k
- Therapeutic Sales SpecialistColumbia, South Carolina10d ago$125k–$185k
- Therapeutic Sales SpecialistJackson, Mississippi10d ago$110k–$165k
- Associate Director, Key AccountsDenver, Colorado10d ago$175k–$250k
- Associate Director, Key AccountsLos Angeles, California10d ago$175k–$250k
- Associate Director, Key AccountsDallas, Texas10d ago$175k–$250k
Divisions
Division information is pending company verification.Once LEO Pharma claims its page, you will see each division, who it calls on and how it pays.
Claim your pageMore from LEO Pharma
These sections fill in when LEO Pharma claims and verifies its page.